Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS
Abstract Objective To examine the effects of common treatments for polycystic ovary syndrome (PCOS) on a panel of hormones (reproductive/metabolic). Design Secondary analysis of blood from a randomized controlled trial of three 16-week preconception interventions designed to improve PCOS-related abn...
Gespeichert in:
| Veröffentlicht in: | The journal of clinical endocrinology and metabolism 2021-01, Vol.106 (1), p.108-119 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 119 |
|---|---|
| container_issue | 1 |
| container_start_page | 108 |
| container_title | The journal of clinical endocrinology and metabolism |
| container_volume | 106 |
| creator | Shah, Aesha Dodson, William C Kris-Etherton, Penny M Kunselman, Allen R Stetter, Christy M Gnatuk, Carol L Estes, Stephanie J Allison, Kelly C Sarwer, David B Sluss, Patrick M Coutifaris, Christos Dokras, Anuja Legro, Richard S |
| description | Abstract
Objective
To examine the effects of common treatments for polycystic ovary syndrome (PCOS) on a panel of hormones (reproductive/metabolic).
Design
Secondary analysis of blood from a randomized controlled trial of three 16-week preconception interventions designed to improve PCOS-related abnormalities: continuous oral contraceptive pills (OCPs, N = 34 subjects), intensive lifestyle modification (Lifestyle, N = 31), or a combination of both (Combined, N = 29).
Materials and Methods
Post-treatment levels of activin A and B, inhibin B, and follistatin (FST), as well as Insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 2 (IGFBP-2), glucagon, glucagon-like peptide 1 (GLP-1) and 2, and oxyntomodulin were compared to baseline, and the change from baseline in these parameters were correlated with outcomes.
Results
Oral contraceptive pill use was associated with a significant suppression in activin A, inhibin A, and anti-mullerian hormone (AMH), but a significant increase in FST. IGF-1, IGFBP-2, glucagon, and GLP-2 levels were significantly decreased. Oxyntomodulin was profoundly suppressed by OCPs (ratio of geometric means: 0.09, 95% confidence interval [CI]: 0.05, 0.18, P |
| doi_str_mv | 10.1210/clinem/dgaa682 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7765645</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1210/clinem/dgaa682</oup_id><sourcerecordid>2445966509</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4952-32b5a708b7ac788de50b0d825ef63eb95bc4ebba40b79e56dbb3616794534a303</originalsourceid><addsrcrecordid>eNqFkc9u1DAQxi0EosvClSOKxAUOaW0ndpILElr1n7RokVokbpbtTLoujh3shGqfpg_TF8NtlgqQENJIc5jffJpvPoReE3xIKMFH2hoH_VF7JSWv6RO0IE3J8oo01VO0wJiSvKno1wP0IsZrjElZsuI5Oihow-salwvUH3cd6DFmvss2Qdps5d0YpIZhNN5l0rXZ2nQQx52F7JNvTWe0fBilOnc6wGhcfOAuT0_yu9vsYhogdLI3dped-dB7BzEzLvu82ly8RM86aSO82vcl-nJyfLk6y9eb0_PVx3Wuy4bRvKCKyQrXqpK6qusWGFa4rSmDjhegGqZ0CUrJEquqAcZbpQpOeJWsF6UscLFEH2bdYVI9tBruPVkxBNPLsBNeGvHnxJmtuPI_RFVxxpPKEr3bCwT_fUr2RW-iBmulAz9FQdMjG84ZbhL69i_02k_BJXuCNowTViQuUYczpYOPMUD3eAzB4j5JMScp9kmmhTe_W3jEf0WXADoDN96OEOI3O91AEFuQdtz-W_X9vOSn4X8X_ASnHb1s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2956153665</pqid></control><display><type>article</type><title>Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Shah, Aesha ; Dodson, William C ; Kris-Etherton, Penny M ; Kunselman, Allen R ; Stetter, Christy M ; Gnatuk, Carol L ; Estes, Stephanie J ; Allison, Kelly C ; Sarwer, David B ; Sluss, Patrick M ; Coutifaris, Christos ; Dokras, Anuja ; Legro, Richard S</creator><creatorcontrib>Shah, Aesha ; Dodson, William C ; Kris-Etherton, Penny M ; Kunselman, Allen R ; Stetter, Christy M ; Gnatuk, Carol L ; Estes, Stephanie J ; Allison, Kelly C ; Sarwer, David B ; Sluss, Patrick M ; Coutifaris, Christos ; Dokras, Anuja ; Legro, Richard S</creatorcontrib><description>Abstract
Objective
To examine the effects of common treatments for polycystic ovary syndrome (PCOS) on a panel of hormones (reproductive/metabolic).
Design
Secondary analysis of blood from a randomized controlled trial of three 16-week preconception interventions designed to improve PCOS-related abnormalities: continuous oral contraceptive pills (OCPs, N = 34 subjects), intensive lifestyle modification (Lifestyle, N = 31), or a combination of both (Combined, N = 29).
Materials and Methods
Post-treatment levels of activin A and B, inhibin B, and follistatin (FST), as well as Insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 2 (IGFBP-2), glucagon, glucagon-like peptide 1 (GLP-1) and 2, and oxyntomodulin were compared to baseline, and the change from baseline in these parameters were correlated with outcomes.
Results
Oral contraceptive pill use was associated with a significant suppression in activin A, inhibin A, and anti-mullerian hormone (AMH), but a significant increase in FST. IGF-1, IGFBP-2, glucagon, and GLP-2 levels were significantly decreased. Oxyntomodulin was profoundly suppressed by OCPs (ratio of geometric means: 0.09, 95% confidence interval [CI]: 0.05, 0.18, P < 0.001). None of the analytes were significantly affected by Lifestyle, whereas the effects of Combined were similar to OCPs alone, although attenuated. Oxyntomodulin was significantly positively associated with the change in total ovarian volume (rs = 0.27; 95% CI: 0.03, 0.48; P = 0.03) and insulin sensitivity index (rs = 0.48; 95% CI: 0.27, 0.64; P < 0.001), and it was inversely correlated with change in area under the curve (AUC) glucose [rs = -0.38; 95% CI: -0.57, -0.16; P = 0.001]. None of the hormonal changes were associated with live birth, only Activin A was associated with ovulation (risk ratio per 1 ng/mL increase in change in Activin A: 6.0 [2.2, 16.2]; P < 0.001).
Conclusions
In women with PCOS, OCPs (and not Lifestyle) affect a wide variety of reproductive/metabolic hormones, but their treatment response does not correlate with live birth.</description><identifier>ISSN: 0021-972X</identifier><identifier>ISSN: 1945-7197</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/clinem/dgaa682</identifier><identifier>PMID: 32968804</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Activin ; Adolescent ; Adult ; Behavior Therapy - methods ; Clinical s ; Combined Modality Therapy ; Contraception ; Contraceptives, Oral - pharmacology ; Contraceptives, Oral - therapeutic use ; Female ; Follistatin ; Glucagon ; Glucagon-like peptide 1 ; Hormones ; Hormones - blood ; Humans ; Incretins - blood ; Inhibin ; Insulin ; Insulin-like growth factor I ; Insulin-like growth factor-binding protein 2 ; Insulin-like growth factors ; Life Style ; Lifestyles ; Metabolism ; Obesity - blood ; Obesity - complications ; Obesity - therapy ; Oral contraceptives ; Ovulation ; Polycystic ovary syndrome ; Polycystic Ovary Syndrome - blood ; Polycystic Ovary Syndrome - complications ; Polycystic Ovary Syndrome - therapy ; Retrospective Studies ; Transforming Growth Factor beta - blood ; Treatment Outcome ; United States ; Young Adult</subject><ispartof>The journal of clinical endocrinology and metabolism, 2021-01, Vol.106 (1), p.108-119</ispartof><rights>The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2020</rights><rights>Copyright © Oxford University Press 2015</rights><rights>The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><rights>The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4952-32b5a708b7ac788de50b0d825ef63eb95bc4ebba40b79e56dbb3616794534a303</citedby><cites>FETCH-LOGICAL-c4952-32b5a708b7ac788de50b0d825ef63eb95bc4ebba40b79e56dbb3616794534a303</cites><orcidid>0000-0001-6012-4900 ; 0000-0001-9927-7584</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32968804$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shah, Aesha</creatorcontrib><creatorcontrib>Dodson, William C</creatorcontrib><creatorcontrib>Kris-Etherton, Penny M</creatorcontrib><creatorcontrib>Kunselman, Allen R</creatorcontrib><creatorcontrib>Stetter, Christy M</creatorcontrib><creatorcontrib>Gnatuk, Carol L</creatorcontrib><creatorcontrib>Estes, Stephanie J</creatorcontrib><creatorcontrib>Allison, Kelly C</creatorcontrib><creatorcontrib>Sarwer, David B</creatorcontrib><creatorcontrib>Sluss, Patrick M</creatorcontrib><creatorcontrib>Coutifaris, Christos</creatorcontrib><creatorcontrib>Dokras, Anuja</creatorcontrib><creatorcontrib>Legro, Richard S</creatorcontrib><title>Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>Abstract
Objective
To examine the effects of common treatments for polycystic ovary syndrome (PCOS) on a panel of hormones (reproductive/metabolic).
Design
Secondary analysis of blood from a randomized controlled trial of three 16-week preconception interventions designed to improve PCOS-related abnormalities: continuous oral contraceptive pills (OCPs, N = 34 subjects), intensive lifestyle modification (Lifestyle, N = 31), or a combination of both (Combined, N = 29).
Materials and Methods
Post-treatment levels of activin A and B, inhibin B, and follistatin (FST), as well as Insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 2 (IGFBP-2), glucagon, glucagon-like peptide 1 (GLP-1) and 2, and oxyntomodulin were compared to baseline, and the change from baseline in these parameters were correlated with outcomes.
Results
Oral contraceptive pill use was associated with a significant suppression in activin A, inhibin A, and anti-mullerian hormone (AMH), but a significant increase in FST. IGF-1, IGFBP-2, glucagon, and GLP-2 levels were significantly decreased. Oxyntomodulin was profoundly suppressed by OCPs (ratio of geometric means: 0.09, 95% confidence interval [CI]: 0.05, 0.18, P < 0.001). None of the analytes were significantly affected by Lifestyle, whereas the effects of Combined were similar to OCPs alone, although attenuated. Oxyntomodulin was significantly positively associated with the change in total ovarian volume (rs = 0.27; 95% CI: 0.03, 0.48; P = 0.03) and insulin sensitivity index (rs = 0.48; 95% CI: 0.27, 0.64; P < 0.001), and it was inversely correlated with change in area under the curve (AUC) glucose [rs = -0.38; 95% CI: -0.57, -0.16; P = 0.001]. None of the hormonal changes were associated with live birth, only Activin A was associated with ovulation (risk ratio per 1 ng/mL increase in change in Activin A: 6.0 [2.2, 16.2]; P < 0.001).
Conclusions
In women with PCOS, OCPs (and not Lifestyle) affect a wide variety of reproductive/metabolic hormones, but their treatment response does not correlate with live birth.</description><subject>Activin</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Behavior Therapy - methods</subject><subject>Clinical s</subject><subject>Combined Modality Therapy</subject><subject>Contraception</subject><subject>Contraceptives, Oral - pharmacology</subject><subject>Contraceptives, Oral - therapeutic use</subject><subject>Female</subject><subject>Follistatin</subject><subject>Glucagon</subject><subject>Glucagon-like peptide 1</subject><subject>Hormones</subject><subject>Hormones - blood</subject><subject>Humans</subject><subject>Incretins - blood</subject><subject>Inhibin</subject><subject>Insulin</subject><subject>Insulin-like growth factor I</subject><subject>Insulin-like growth factor-binding protein 2</subject><subject>Insulin-like growth factors</subject><subject>Life Style</subject><subject>Lifestyles</subject><subject>Metabolism</subject><subject>Obesity - blood</subject><subject>Obesity - complications</subject><subject>Obesity - therapy</subject><subject>Oral contraceptives</subject><subject>Ovulation</subject><subject>Polycystic ovary syndrome</subject><subject>Polycystic Ovary Syndrome - blood</subject><subject>Polycystic Ovary Syndrome - complications</subject><subject>Polycystic Ovary Syndrome - therapy</subject><subject>Retrospective Studies</subject><subject>Transforming Growth Factor beta - blood</subject><subject>Treatment Outcome</subject><subject>United States</subject><subject>Young Adult</subject><issn>0021-972X</issn><issn>1945-7197</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9u1DAQxi0EosvClSOKxAUOaW0ndpILElr1n7RokVokbpbtTLoujh3shGqfpg_TF8NtlgqQENJIc5jffJpvPoReE3xIKMFH2hoH_VF7JSWv6RO0IE3J8oo01VO0wJiSvKno1wP0IsZrjElZsuI5Oihow-salwvUH3cd6DFmvss2Qdps5d0YpIZhNN5l0rXZ2nQQx52F7JNvTWe0fBilOnc6wGhcfOAuT0_yu9vsYhogdLI3dped-dB7BzEzLvu82ly8RM86aSO82vcl-nJyfLk6y9eb0_PVx3Wuy4bRvKCKyQrXqpK6qusWGFa4rSmDjhegGqZ0CUrJEquqAcZbpQpOeJWsF6UscLFEH2bdYVI9tBruPVkxBNPLsBNeGvHnxJmtuPI_RFVxxpPKEr3bCwT_fUr2RW-iBmulAz9FQdMjG84ZbhL69i_02k_BJXuCNowTViQuUYczpYOPMUD3eAzB4j5JMScp9kmmhTe_W3jEf0WXADoDN96OEOI3O91AEFuQdtz-W_X9vOSn4X8X_ASnHb1s</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Shah, Aesha</creator><creator>Dodson, William C</creator><creator>Kris-Etherton, Penny M</creator><creator>Kunselman, Allen R</creator><creator>Stetter, Christy M</creator><creator>Gnatuk, Carol L</creator><creator>Estes, Stephanie J</creator><creator>Allison, Kelly C</creator><creator>Sarwer, David B</creator><creator>Sluss, Patrick M</creator><creator>Coutifaris, Christos</creator><creator>Dokras, Anuja</creator><creator>Legro, Richard S</creator><general>Oxford University Press</general><general>Copyright Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TM</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6012-4900</orcidid><orcidid>https://orcid.org/0000-0001-9927-7584</orcidid></search><sort><creationdate>20210101</creationdate><title>Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS</title><author>Shah, Aesha ; Dodson, William C ; Kris-Etherton, Penny M ; Kunselman, Allen R ; Stetter, Christy M ; Gnatuk, Carol L ; Estes, Stephanie J ; Allison, Kelly C ; Sarwer, David B ; Sluss, Patrick M ; Coutifaris, Christos ; Dokras, Anuja ; Legro, Richard S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4952-32b5a708b7ac788de50b0d825ef63eb95bc4ebba40b79e56dbb3616794534a303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Activin</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Behavior Therapy - methods</topic><topic>Clinical s</topic><topic>Combined Modality Therapy</topic><topic>Contraception</topic><topic>Contraceptives, Oral - pharmacology</topic><topic>Contraceptives, Oral - therapeutic use</topic><topic>Female</topic><topic>Follistatin</topic><topic>Glucagon</topic><topic>Glucagon-like peptide 1</topic><topic>Hormones</topic><topic>Hormones - blood</topic><topic>Humans</topic><topic>Incretins - blood</topic><topic>Inhibin</topic><topic>Insulin</topic><topic>Insulin-like growth factor I</topic><topic>Insulin-like growth factor-binding protein 2</topic><topic>Insulin-like growth factors</topic><topic>Life Style</topic><topic>Lifestyles</topic><topic>Metabolism</topic><topic>Obesity - blood</topic><topic>Obesity - complications</topic><topic>Obesity - therapy</topic><topic>Oral contraceptives</topic><topic>Ovulation</topic><topic>Polycystic ovary syndrome</topic><topic>Polycystic Ovary Syndrome - blood</topic><topic>Polycystic Ovary Syndrome - complications</topic><topic>Polycystic Ovary Syndrome - therapy</topic><topic>Retrospective Studies</topic><topic>Transforming Growth Factor beta - blood</topic><topic>Treatment Outcome</topic><topic>United States</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shah, Aesha</creatorcontrib><creatorcontrib>Dodson, William C</creatorcontrib><creatorcontrib>Kris-Etherton, Penny M</creatorcontrib><creatorcontrib>Kunselman, Allen R</creatorcontrib><creatorcontrib>Stetter, Christy M</creatorcontrib><creatorcontrib>Gnatuk, Carol L</creatorcontrib><creatorcontrib>Estes, Stephanie J</creatorcontrib><creatorcontrib>Allison, Kelly C</creatorcontrib><creatorcontrib>Sarwer, David B</creatorcontrib><creatorcontrib>Sluss, Patrick M</creatorcontrib><creatorcontrib>Coutifaris, Christos</creatorcontrib><creatorcontrib>Dokras, Anuja</creatorcontrib><creatorcontrib>Legro, Richard S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shah, Aesha</au><au>Dodson, William C</au><au>Kris-Etherton, Penny M</au><au>Kunselman, Allen R</au><au>Stetter, Christy M</au><au>Gnatuk, Carol L</au><au>Estes, Stephanie J</au><au>Allison, Kelly C</au><au>Sarwer, David B</au><au>Sluss, Patrick M</au><au>Coutifaris, Christos</au><au>Dokras, Anuja</au><au>Legro, Richard S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>106</volume><issue>1</issue><spage>108</spage><epage>119</epage><pages>108-119</pages><issn>0021-972X</issn><issn>1945-7197</issn><eissn>1945-7197</eissn><abstract>Abstract
Objective
To examine the effects of common treatments for polycystic ovary syndrome (PCOS) on a panel of hormones (reproductive/metabolic).
Design
Secondary analysis of blood from a randomized controlled trial of three 16-week preconception interventions designed to improve PCOS-related abnormalities: continuous oral contraceptive pills (OCPs, N = 34 subjects), intensive lifestyle modification (Lifestyle, N = 31), or a combination of both (Combined, N = 29).
Materials and Methods
Post-treatment levels of activin A and B, inhibin B, and follistatin (FST), as well as Insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 2 (IGFBP-2), glucagon, glucagon-like peptide 1 (GLP-1) and 2, and oxyntomodulin were compared to baseline, and the change from baseline in these parameters were correlated with outcomes.
Results
Oral contraceptive pill use was associated with a significant suppression in activin A, inhibin A, and anti-mullerian hormone (AMH), but a significant increase in FST. IGF-1, IGFBP-2, glucagon, and GLP-2 levels were significantly decreased. Oxyntomodulin was profoundly suppressed by OCPs (ratio of geometric means: 0.09, 95% confidence interval [CI]: 0.05, 0.18, P < 0.001). None of the analytes were significantly affected by Lifestyle, whereas the effects of Combined were similar to OCPs alone, although attenuated. Oxyntomodulin was significantly positively associated with the change in total ovarian volume (rs = 0.27; 95% CI: 0.03, 0.48; P = 0.03) and insulin sensitivity index (rs = 0.48; 95% CI: 0.27, 0.64; P < 0.001), and it was inversely correlated with change in area under the curve (AUC) glucose [rs = -0.38; 95% CI: -0.57, -0.16; P = 0.001]. None of the hormonal changes were associated with live birth, only Activin A was associated with ovulation (risk ratio per 1 ng/mL increase in change in Activin A: 6.0 [2.2, 16.2]; P < 0.001).
Conclusions
In women with PCOS, OCPs (and not Lifestyle) affect a wide variety of reproductive/metabolic hormones, but their treatment response does not correlate with live birth.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>32968804</pmid><doi>10.1210/clinem/dgaa682</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-6012-4900</orcidid><orcidid>https://orcid.org/0000-0001-9927-7584</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-972X |
| ispartof | The journal of clinical endocrinology and metabolism, 2021-01, Vol.106 (1), p.108-119 |
| issn | 0021-972X 1945-7197 1945-7197 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7765645 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Activin Adolescent Adult Behavior Therapy - methods Clinical s Combined Modality Therapy Contraception Contraceptives, Oral - pharmacology Contraceptives, Oral - therapeutic use Female Follistatin Glucagon Glucagon-like peptide 1 Hormones Hormones - blood Humans Incretins - blood Inhibin Insulin Insulin-like growth factor I Insulin-like growth factor-binding protein 2 Insulin-like growth factors Life Style Lifestyles Metabolism Obesity - blood Obesity - complications Obesity - therapy Oral contraceptives Ovulation Polycystic ovary syndrome Polycystic Ovary Syndrome - blood Polycystic Ovary Syndrome - complications Polycystic Ovary Syndrome - therapy Retrospective Studies Transforming Growth Factor beta - blood Treatment Outcome United States Young Adult |
| title | Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T04%3A15%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Oral%20Contraception%20and%20Lifestyle%20Modification%20on%20Incretins%20and%20TGF-%C3%9F%20Superfamily%20Hormones%20in%20PCOS&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Shah,%20Aesha&rft.date=2021-01-01&rft.volume=106&rft.issue=1&rft.spage=108&rft.epage=119&rft.pages=108-119&rft.issn=0021-972X&rft.eissn=1945-7197&rft_id=info:doi/10.1210/clinem/dgaa682&rft_dat=%3Cproquest_pubme%3E2445966509%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2956153665&rft_id=info:pmid/32968804&rft_oup_id=10.1210/clinem/dgaa682&rfr_iscdi=true |